The pricing of Nurix's upsized public offering and the issuance of pre-funded warrants are significant capital-raising activities. While this could dilute existing shares, the influx of capital is likely aimed at funding ongoing research and development, which could have long-term benefits. The short-term impact on the stock price could be neutral as the market absorbs the news of dilution and potential for future growth.